photoactivator

photoactivator

Any ingested substance that enhances reactivity to light—e.g., PUVA, tetracycline, psoralens (celery, figs, parsley).

photoactivator

Any ingested substance that enhances reactivity to light–eg, PUVA, tetracycline, psoralens–eg, celery, parsley. See PUVA.
References in periodicals archive ?
Photocuring of monomers is a common method that involves the use of a photoactivator system that is capable of absorbing ultraviolet or visible radiation wavelengths to convert a monomer into a cross linked system [1].
With the addition of Novus TTx to our existing photocoagulator, SLT, photoactivator and photodisruptor platforms, Lumenis offers a minimally-invasive option for nearly every major eye disease.
Opal Photoactivator laser for AMD (age-related macluar
Food and Drug Administration (FDA) Ophthalmic Drugs Subcommittee recommended approval of the Opal(TM) Photoactivator and Visudyne Therapy for the wet form of age-related macular degeneration (AMD).
Nasdaq: QLTI), covers Coherent's new Opal Photoactivator laser, as well as Visudyne, the drug which is activated by the special purpose 689nm diode laser device.
Food and Drug Administration (FDA) approved the Opal Photoactivator and Visudyne(TM) (verteporfin for injection) therapy to treat the wet form of Age-Related Macular Degeneration (AMD).
Nasdaq: QLTI), covers Coherent's new OPAL(TM) photoactivator laser, as well as the verteporferin drug which is activated by the special purpose 689nm diode laser device.
Nasdaq: QLTI), covers Coherent's Opal Photoactivator laser developed specifically for use in photodynamic therapy and verteporfin for injection, the drug which is activated by this special purpose 689nm-diode laser.
The FDA has indicated they will, after final review, approve the Opal Photoactivator concluding Visudyne therapy was most appropriate for patients with the wet form of AMD, characterized by the presence of predominantly classic Subfoveal Choroidal Neovascularization (CNV), the indication sought for in the joint drug / device submission.
Food and Drug Administration (FDA) approval of the Opal(TM) Photoactivator laser (used for the treatment of the wet form of age-related macular degeneration) should help this trend continue.
This important step clears Coherent's Opal(TM) Photoactivator laser, already CE mark approved, for the treatment of many thousands of patients who lose vision every year.
A number of techniques can be used to modify substrate surfaces (abrasion, photoactivators, and chemical agents, to name a few) but in recent years research has focused on processes that can change substrate surfaces without altering the general properties of the solids themselves (heat or electrical treatments).